Annual report pursuant to Section 13 and 15(d)

Note 15 - Segments - Segment Information (Details)

v3.22.1
Note 15 - Segments - Segment Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue from contract with customer $ 46,000 $ 119,000
Grant and other revenue 485,898 796,288
Revenues, Total 531,513 915,013
Research and development expenses, excluding depreciation and amortization 5,141,910 4,930,187
Selling, general and administrative expenses, excluding depreciation and amortization [1] 7,373,061 6,624,566
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 76,954 70,393
Loss from operations [3] (12,060,412) (10,711,181)
Other income (4) [4] 345,524 (10,510)
Provision for income taxes (16,043) 0
Net loss (11,730,931) (10,721,691)
Total assets, net of depreciation and amortization 6,644,833 7,758,018
Capital expenditures 25,218 135,881
Cost of revenue 0 1,048
Research and Development Expense, Total 5,141,910 4,930,187
UNITED STATES    
Total assets, net of depreciation and amortization 6,433,962 7,555,227
Non-US [Member]    
Total assets, net of depreciation and amortization 210,871 202,791
Royalty [Member]    
Revenue from contract with customer 0 7,995
License [Member]    
Revenue from contract with customer 45,615 110,730
Diagnostics Segment [Member]    
Grant and other revenue 485,898 482,221
Revenues, Total 531,513 600,946
Research and development expenses, excluding depreciation and amortization 4,488,177 4,593,459
Selling, general and administrative expenses, excluding depreciation and amortization [1] 0 299,959
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 24,162 10,068
Loss from operations [3] (3,980,826) (4,303,588)
Other income (4) [4] 0 0
Provision for income taxes (5,452)  
Net loss (3,986,278) (4,303,588)
Capital expenditures 0 120,810
Cost of revenue   1,048
Research and Development Expense, Total 4,488,177 4,593,459
Diagnostics Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 107,931 139,121
Diagnostics Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization 210,281 202,791
Diagnostics Segment [Member] | Royalty [Member]    
Revenue from contract with customer 0 7,995
Diagnostics Segment [Member] | License [Member]    
Revenue from contract with customer 45,615 110,730
Therapeutics Segment [Member]    
Grant and other revenue 0 314,067
Revenues, Total 0 314,067
Research and development expenses, excluding depreciation and amortization 653,733 336,728
Selling, general and administrative expenses, excluding depreciation and amortization [1] 4,438 800
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 0 0
Loss from operations [3] (658,171) (23,461)
Other income (4) [4] 0 0
Provision for income taxes (901)  
Net loss (659,072) (23,461)
Capital expenditures 0 0
Cost of revenue   0
Research and Development Expense, Total 653,733 336,728
Therapeutics Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 0 0
Therapeutics Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization 0 0
Therapeutics Segment [Member] | Royalty [Member]    
Revenue from contract with customer 0 0
Therapeutics Segment [Member] | License [Member]    
Revenue from contract with customer 0 0
Corporate Segment [Member]    
Grant and other revenue 0 0
Revenues, Total 0 0
Research and development expenses, excluding depreciation and amortization 0 0
Selling, general and administrative expenses, excluding depreciation and amortization [1] 7,368,623 6,323,807
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 52,792 60,325
Loss from operations [3] (7,421,415) (6,384,132)
Other income (4) [4] 345,524 (10,510)
Provision for income taxes (9,690)  
Net loss (7,085,581) (6,394,642)
Capital expenditures 25,218 15,071
Cost of revenue   0
Research and Development Expense, Total 0 0
Corporate Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 6,326,031 7,416,106
Corporate Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization 590 0
Corporate Segment [Member] | Royalty [Member]    
Revenue from contract with customer 0 0
Corporate Segment [Member] | License [Member]    
Revenue from contract with customer $ 0 $ 0
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($76,954 and $70,393 for the years ended December 31, 2021 and 2020, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4] Amounts consist primarily of gain on extinguishment of debt, interest income and interest expense, which are not currently allocated to our individual reportable segments.